Publications by authors named "Ocampo-Garza S"
Article Synopsis
- Acne keloidalis nuchae (AKN) is a type of scarring hair loss more prevalent in individuals of African descent, and this study focuses on its occurrence in Hispanic patients.
- A retrospective study involving 142 patients from dermatological centers in several Latin American countries found that the majority were young males with a significant history of trauma in the nuchal area.
- The findings suggest that AKN should be considered in Hispanic populations, as those with longer-term symptoms tend to present with more severe disease stages.
Introduction: Dysgeusia may occur during conventional or target-therapies and affect patients adherence-to-treatment. Therefore, it should be monitored to improve clinical outcome. To date, available questionnaires on dysgeusia relate to traditional antineoplastics and do not apply to target-therapies as the pathogenetic mechanism and clinical expression differ.
View Article and Find Full Text PDFArticle Synopsis
- * A 56-year-old woman developed psoriatic alopecia and paradoxical psoriasis after starting adalimumab but improved after switching to certolizumab, with her condition assessed via trichoscopy and reflectance confocal microscopy.
- * Certolizumab is noted for having a lower risk of causing paradoxical reactions compared to other anti-TNF-α agents and is considered a safe, effective treatment option for managing psoriasis and psoriatic arthritis.
Hair loss in elderly patients is a common complaint. It can be related to different conditions that affect patients' quality of life and represents a challenge for dermatologists. It affects both men and women during the aging process with an estimated percentage of balding after 65 years of age of 53% and 37%, respectively.
View Article and Find Full Text PDFNowadays, the biological equipment available for the treatment of moderate-to-severe psoriasis is plenty. Anti-interleukin-23 represents the latest class of biologic approved for the management of moderate-to-severe psoriasis. Their efficacy and safety have been assessed through two major sources: clinical trials (CTs) and real-world experiences data (RWE).
View Article and Find Full Text PDFArticle Synopsis
- * A review of literature over the past five years focused on identifying biomarkers that could help personalize treatments for psoriasis, particularly for therapies like phototherapy and biologics.
- * The HLA-C*02:06 gene shows promise as a biomarker associated with psoriasis treatment responses, but more research is needed to establish reliable biomarkers due to inconsistencies across studies.
Alopecia universalis improvement following risankizumab in a psoriasis patient.
J Eur Acad Dermatol Venereol
July 2022
Psoriasis and psoriatic arthritis (PsA) development is sustained by tumor necrosis factor (TNF)α, interleukin (IL)17, and IL23; hence, biologics targeting those cytokines represent useful therapeutic weapons for both conditions. Nevertheless, biologics strongly reduce PsA risk; several studies reported the possibility of new-onset PsA during biologic therapy for psoriasis. The aim of this 1-year prospective study is to evaluate the prevalence of paradoxical PsA in psoriasis patients under biologic therapy and review the existing literature.
View Article and Find Full Text PDFIntroduction: Cutaneous squamous cell carcinoma (CSCC) is the second most frequent malignant skin cancer, with an increasing worldwide incidence. Cemiplimab is a human monoclonal antibody directed against programmed cell death-1 receptor that acts by blocking T-cell inactivation. It is the first drug approved for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.
View Article and Find Full Text PDF